Sugi Predict

Sugi Predict / Compounds / SCHEMBL7899994

SCHEMBL7899994

SCHEMBL7899994

CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)O)O1

nearest known ligand 0.85

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 12/20 0.85
▸ LMNA P02545 5/20 0.85
▸ HIF1A Q16665 4/20 0.85
▸ PGR P06401 4/20 0.85
▸ AR P10275 2/20 0.85
▸ CYP3A4 P08684 2/20 0.85
▸ MAPT P10636 1/20 0.85
▸ HSD17B10 Q99714 1/20 0.85
▸ TDP1 Q9NUW8 1/20 0.85
▸ KDM4E B2RXH2 1/20 0.85
▸ MAPK1 P28482 1/20 0.85
▸ ALDH1A1 P00352 1/20 0.79
▸ MEN1 O00255 1/20 0.79
▸ KMT2A Q03164 1/20 0.79
▸ NR1I2 O75469 1/20 0.61
▸ ESR1 P03372 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24622511 1.00 NR3C1 (0.85) NR3C1LMNAHIF1APGRAR
SCHEMBL11436422 1.00 NR3C1 (0.85) NR3C1LMNAHIF1APGRAR
SCHEMBL6324045 0.95 NR3C1 (0.80) NR3C1LMNAHIF1APGRAR
SCHEMBL11733697 0.95 NR3C1 (0.82) NR3C1LMNAHIF1APGRAR
SCHEMBL13178131 0.94 NR3C1 (0.81) NR3C1LMNAHIF1APGRAR
SCHEMBL24622359 0.94 NR3C1 (0.81) NR3C1LMNAHIF1APGRAR
SCHEMBL13178133 0.94 NR3C1 (0.81) NR3C1LMNAHIF1APGRAR
Fluocinolone Acetonide SCHEMBL12323210 0.92 NR3C1 (1.00) NR3C1LMNAHIF1APGRAR
Fluocinolone Acetonide SCHEMBL15256220 0.92 NR3C1 (1.00) NR3C1LMNAHIF1APGRAR
Fluocinolone Acetonide SCHEMBL21153661 0.92 NR3C1 (1.00) NR3C1LMNAHIF1APGRAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6197761-B1 ANTIINFLAMMATORY, ANTALLERGEN AGENTS GLAXO WELLCOME INC. 2001-03-06 — — US claimed
EP-0876392-B1 LACTONE DERIVATIVES OF 17.BETA.-CARBOXY, CARBOTHIO AND AMIDE ANDROSTANE DERIVATIVES GLAXO GROUP LTD (GB) 2000-07-05 — — EP claimed
EP-0876392-A1 LACTONE DERIVATIVES OF 17.BETA.-CARBOXY, CARBOTHIO AND AMIDE ANDROSTANE DERIVATIVES GLAXO GROUP LIMITED (GB) 1998-11-11 — — EP claimed
WO-1997024365-A1 LACTONE DERIVATIVES OF 17.BETA.-CARBOXY, CARBOTHIO AND AMIDE ANDROSTANE DERIVATIVES GLAXO GROUP LIMITED (GB) 1997-07-10 — — WO claimed
EP-0197018-B1 16,17-ACETAL-SUBSTITUTED ANDROSTANE-17-BETA-CARBOXYLIC-ACID ESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOUND CONTAINING THEM Aktiebolaget Draco (SE) 1992-12-09 — — EP claimed
WO-2024059237-A2 NOVEL GLUCOCORTICOID RECEPTOR AGONISTS AND IMMUNOCONJUGATES THEREOF ADCENTRX THERAPEUTICS INC. (US) 2024-03-21 — — WO disclosed
WO-2022150637-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF IMMUNEXT, INC. (US) 2022-07-14 — — WO disclosed
US-20110294766-A1 16 Alpha, 17 Alpha-Acetal Glucocorticosteroidal Derivatives and their Use ASTRAZENECA AB (SE) 2011-12-01 — — US disclosed
US-20110294766-A1 16 Alpha, 17 Alpha-Acetal Glucocorticosteroidal Derivatives and their Use ASTRAZENECA AB (SE) 2011-12-01 — — US disclosed
WO-2009108118-A9 16 ALPHA, 17 ALPHA-ACETAL GLUCOCORTICOSTEROIDAL DERIVATIVES AND THEIR USE ASTRAZENECA AB (SE) 2010-09-02 — — WO disclosed
WO-2009108118-A1 16 ALPHA, 17 ALPA-ACETAL GLUCOCORTICOSTEROIDAL DERIVATIVES AND THEIR USE ASTRAZENECA AB (SE) 2009-09-03 — — WO disclosed
US-6197761-B1 ANTIINFLAMMATORY, ANTALLERGEN AGENTS GLAXO WELLCOME INC. 2001-03-06 — — US disclosed
EP-0197018-B1 16,17-ACETAL-SUBSTITUTED ANDROSTANE-17-BETA-CARBOXYLIC-ACID ESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOUND CONTAINING THEM Aktiebolaget Draco (SE) 1992-12-09 — — EP disclosed
US-4950659-A ANTIINFLAMMATORY AGENTS AKTIEBOLAGET DRACO (SE) 1990-08-21 — — US disclosed
EP-0355859-A1 Process for the preparation of intermediates for 11-beta,16-alpha,17-alpha,21-tetrahydroxypregna-3,20-dione 16-alpha,17-alpha-acetals and 21-esters thereof Aktiebolaget Draco (SE) 1990-02-28 — — EP disclosed
US-4335121-A TOPICAL ANTIINFLAMMATORY AGENTS GLAXO GROUP LIMITED (GB) 1982-06-15 — — US disclosed
EP-0004741-B1 THIO ETIANIC ACID DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL USE SYNTEX (U.S.A.) INC. (US) 1981-01-28 — — EP disclosed
US-4198336-A Chemical process for preparing androsta-4-ene 17α-carboxylic acids SYNTEX (U.S.A.) INC. (US) 1980-04-15 — — US disclosed
EP-0004741-A2 Thio etianic acid derivatives, their preparation and pharmaceutical use SYNTEX (U.S.A.) INC. (US) 1979-10-17 — — EP disclosed
US-4119625-A Process for the manufacture of steroid carboxylic acids and the esters thereof CIBA-GEIGY CORPORATION (US) 1978-10-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294766-A1 16 Alpha, 17 Alpha-Acetal Glucocorticosteroidal Derivatives and their Use CYP17A1, HSD17B7, NR5A1 NR3C1 15/4885LMNA 2494/4885HIF1A 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback